| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Medprin Regenerative Medical Technologies Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥28.28 |
| 52 Week High | CN¥53.00 |
| 52 Week Low | CN¥22.37 |
| Beta | -0.24 |
| 1 Month Change | -18.50% |
| 3 Month Change | -28.71% |
| 1 Year Change | -35.81% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -60.19% |
Recent News & Updates
Recent updates
Shareholder Returns
| 301033 | CN Medical Equipment | CN Market | |
|---|---|---|---|
| 7D | -8.2% | -6.2% | -4.9% |
| 1Y | -35.8% | -25.0% | -21.1% |
Return vs Industry: 301033 underperformed the CN Medical Equipment industry which returned -25% over the past year.
Return vs Market: 301033 underperformed the CN Market which returned -21.1% over the past year.
Price Volatility
| 301033 volatility | |
|---|---|
| 301033 Average Weekly Movement | 11.8% |
| Medical Equipment Industry Average Movement | 8.0% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.4% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 301033's share price has been volatile over the past 3 months.
Volatility Over Time: 301033's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 279 | Yuyu Yuan | www.medprin.com |
Medprin Regenerative Medical Technologies Co., Ltd. engages in the research, development, manufacture, and sale of implantable medical devices. The company offers dura membrane patches, regenerated oxidized cellulose, and craniomaxillofacial repair systems.
Medprin Regenerative Medical Technologies Co., Ltd. Fundamentals Summary
| 301033 fundamental statistics | |
|---|---|
| Market cap | CN¥1.71b |
| Earnings (TTM) | CN¥31.28m |
| Revenue (TTM) | CN¥201.78m |
59.7x
P/E Ratio9.3x
P/S RatioIs 301033 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 301033 income statement (TTM) | |
|---|---|
| Revenue | CN¥201.78m |
| Cost of Revenue | CN¥38.42m |
| Gross Profit | CN¥163.36m |
| Other Expenses | CN¥132.08m |
| Earnings | CN¥31.28m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Apr 19, 2024
| Earnings per share (EPS) | 0.47 |
| Gross Margin | 80.96% |
| Net Profit Margin | 15.50% |
| Debt/Equity Ratio | 8.7% |
How did 301033 perform over the long term?
See historical performance and comparison